Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 4:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Cervical Cancer
Interventions: Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab, Paclitaxel, Cisplatin, Carboplatin, Rescue Medications; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 34
States / cities: Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 29 more

Conditions: Asthma
Interventions: One time music therapy, Group music therapy; Other
Lead sponsor: Beth Israel Medical Center; Other
Eligibility: 7 Years to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Other; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 20
States / cities: Anaheim, California • Los Angeles, California • Santa Rosa, California + 16 more

Conditions: Cyberbullying
Interventions: IMPACT Intervention, Control: Enhanced Online Resources (EOR); Behavioral · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 13 Years to 17 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Renal Impairment
Interventions: tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
Interventions: PLX7486 TsOH; Drug
Lead sponsor: Plexxikon; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Leukemia, HOX Gene
Interventions: Revumenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Metastatic Renal Cell Carcinoma, Kidney Cancer
Interventions: Bevacizumab and Sunitinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers, Anemia, Sickle Cell
Interventions: AG-946, AG-946 Matched Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York + 4 more

Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
Interventions: ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Plantation, Florida • St Louis, Missouri • Fairfax, Virginia

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
Interventions: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Mental Health, Parenting / Maternal Behavior, Parenting Anxiety, Parenting Behavior, Stress, Psychological Distress, Depression and Anxiety Symptoms, Internalizing Problems, Externalizing Problems
Interventions: Healing Hearts, electronic New Beginnings Program, Curated internet resources; Behavioral
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stamford, Connecticut

Conditions: Solid Tumors, Adult
Interventions: HMPL-A251; Drug
Lead sponsor: Hutchmed; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 8
States / cities: Denver, Colorado • Plantation, Florida • Tamarac, Florida + 4 more

Conditions: Cancer
Interventions: JTX-2011, Nivolumab, Ipilimumab, Pembrolizumab; Drug
Lead sponsor: Jounce Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 16
States / cities: Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 11 more

Conditions: Metastatic Uveal Melanoma
Interventions: Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatic Impairment
Interventions: Nalbuphine ER; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: H. Pylori Infection, Gastric Cancer, Gastritis H Pylori
Interventions: PYTEST® 14C-Urea Capsule Breath Test (at Home), PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person); Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Myeloma
Interventions: VELCADE™; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Constipation
Interventions: Prucalopride, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more

Conditions: Sleep-disordered Breathing
Interventions: Zolpidem, No Treatment; Drug · Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Alzheimer's Disease
Interventions: Placebo, Gantenerumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 30
States / cities: Sun City, Arizona • Tucson, Arizona • Costa Mesa, California + 27 more

Conditions: GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions: RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide; Drug
Lead sponsor: RayzeBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 32
States / cities: Phoenix, Arizona • Duarte, California • Irvine, California + 27 more

Conditions: Lymphoma, Mantle Cell, Mantle Cell Lymphoma
Interventions: Rituximab (R), EPOCH, Bortezomib (B), Bortezomib, Bortezomib or observation; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy, Type 2 Diabetes Mellitus
Interventions: LY3938577, Placebo, Insulin degludec; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • Dallas, Texas

Search by objective public record fields.

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

The Effects of Music Therapy as a Complementary Intervention in the Treatment of Pediatric Asthma

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

Intervention Media to Prevent Adolescent Cyber-conflict Through Technology

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Healing Hearts: A Mindfulness App for Parents Navigating Divorce or Separation

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

Tebentafusp-tebn With LDT in Metastatic UM

Study of Nalbuphine ER in Participants With Hepatic Impairment

Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

A Study of Prucalopride For Functional Constipation in Children and Teenagers

Sleep and Breathing in the General Population - Chemical Stimuli

A Study of Gantenerumab in Participants With Mild Alzheimer Disease

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus